

SEVENTH  
INTERNATIONAL  
MEETING

on HIV Infection  
of the Central  
Nervous System

# NeuroHIV

Pollenzo - Bra (CN), Italy - Albergo dell'Agenzia

October, 12<sup>th</sup>-14<sup>th</sup> 2017

PRELIMINARY  
PROGRAMME

[www.neurohiv.com](http://www.neurohiv.com)



# Patronage requested

COMUNE DI BRA

ISS (ISTITUTO SUPERIORE DI SANITÀ)

MINISTERO DELLA SALUTE

REGIONE PIEMONTE

UNIVERSITÀ DEGLI STUDI DI ROMA "TOR VERGATA"

UNIVERSITÀ VITA-SALUTE SAN RAFFAELE

INMI "LAZZARO SPALLANZANI"

IRCCS SAN RAFFAELE

S.I.M.I.T

SIV-ISV

# PRESENTATION

The incidence of the most threatening complications of HIV infection (HIV associated dementia) has dramatically decreased among people receiving combination antiretroviral treatments although a new spectrum of neurological and neuropsychiatric problems has emerged as a challenge for the coming years.

In the last years earlier start of the antiretroviral therapy and the more exclusive use of combination including new drugs, integrase inhibitor in particular, with better performances in term of efficacy and toxicity require an update on this topic.

Neurocognitive impairment is one of the main concern, and research studies investigating causes, extent, phenotypes and monitoring are under way. Potential loss of control of HIV replication in the CNS is also of concern because it may be associated with more severe neurological disease.

Why does this occur, how often and how can we recognize it, are also questions waiting for answers. In this regard, particular attention is required when switching from older "neuroprotective" drug combinations to newer therapeutic approaches, including simplified regimens. On the other hand, the potential CNS toxicity of ARV drugs is also emerging as a focus of particular attention. Finally, CNS cells may harbor HIV during systemically controlled infection and serve as potential viral reservoirs that are relevant to systemic approaches to HIV eradication.

The goal of this meeting is to update, discuss and review the concepts on HIV brain infection in the current era, addressing unsolved issues and discussing control strategies for the future.

# Scientific Committee

Andrea Antinori  
*Rome, Italy*

Paola Cinque  
*Milan, Italy*

Steven Deeks  
*San Francisco, USA*

Magnus Gisslén  
*Goteborg, Sweden*

Giuseppe Ippolito  
*Rome, Italy*

Adriano Lazzarin  
*Milan, Italy*

Carlo Federico Perno  
*Rome, Italy*

Richard W. Price  
*San Francisco, USA*

Kevin Robertson  
*Chapel Hill, USA*

# FACULTY

**Andrea Antinori**, Rome, Italy

**Stefano Bonora**, Turin, Italy

**Andrea Calcagno**, Turin, Italy

**Antonella Cingolani**, Rome, Italy

**Paola Cinque**, Milan, Italy

**James Cole**, London, UK

**Antonella d'Arminio Monforte**,  
Milan, Italy

**Andrea De Luca**, Siena, Italy

**Steven Deeks**, San Francisco, USA

**Antonio Di Biagio**, Genoa, Italy

**Giovanni Di Perri**, Turin, Italy

**Howard Fox**, Omaha, USA

**Massimo Galli**, Milan, Italy

**Lucio Gama**, Baltimore, USA

**Victor Garcia**, Chapel Hill, USA

**Simonetta Gerevini**, Milan, Italy

**Magnus Gisslen**, Goteborg, Sweden

**Andrea Gori**, Milan, Italy

**Giovanni Guaraldi**, Modena, Italy

**Vanessa Hirsch**, Rockville, USA

**Peter Hunt**, San Francisco, USA

**Giuseppe Ippolito**, Rome, Italy

**Sarah Joseph**, Chapel Hill, USA

**Adriano Lazzarin**, Milan, Italy

**Scott Lee Letendre**, San Diego, USA

**Sergio Lo Caputo**, Florence, Italy

**Franco Maggiolo**, Bergamo, Italy

**Giulia Marchetti**, Milan, Italy

**Esteban Martinez**, Barcelona, Spain

**Cristina Mussini**, Modena, Italy

**Avi Nath**, Bethesda, USA

**Giuseppe Nunnari**, Catania, Italy

**Saverio Parisi**, Padua, Italy

**Carlo Federico Perno**, Rome, Italy

**Deborah Persaud**, Baltimore, USA

**Guido Poli**, Milan, Italy

**Richard W. Price**, San Francisco, USA

**Giuliano Rizzardini**, Milan, Italy

**Kevin Robertson**, Chapel Hill, USA

**Stefano Rusconi**, Milan, Italy

**Serena Spudich**, New Haven, USA

**Ronald Swanstrom**, Chapel Hill, USA

**Alan Winston**, London, UK

**Aylin Yilmaz**, Goteborg, Sweden

# Day I - Thursday, October 12<sup>th</sup>, 2017

08.30am-09.00am Registration  
and Welcome Remarks to the General Meeting

09.00am-01.00pm **Workshop on Nosology and Approach  
to CNS HIV Escape**

*Chairpersons:*

*S. Spudich (New Haven, USA), A. Winston (London, UK)*

*Panel members:*

*A. Antinori (Rome, Italy), P. Cinque (Milan, Italy),*

*H. Fox (Omaha, USA), M. Gisslen (Goteborg, Sweden),*

*S. Letendre (San Diego, USA), D. Persaud (Baltimore, USA),*

*R. Price (San Francisco, USA)*

01.00pm-01.30pm Discussion

01.30pm-02.30pm LUNCH

## **SESSION I - Mechanisms and biomarkers of CNS HIV Infection**

*Chairpersons: M. Galli (Milan, Italy), A. Lazzarin (Milan, Italy)*

02.30pm-03.00pm Myeloid cells in CNS infection: traffic and replication  
*C.F. Perno (Rome, Italy)*

03.00pm-03.30pm CNS viral and cell dynamics in the humanized  
mouse model  
*V. Garcia (Chapel Hill, USA)*

03.30pm-04.00pm Systemic-CNS viral dynamics in a simian HIV-1 infection  
*V. Hirsch (Rockville, USA)*

# Day I - Thursday, October 12<sup>th</sup>, 2017

04.00pm-04.30pm Systemic-CNS viral dynamics in a human  
HIV-1 infection  
*R. Swanstrom* (Chapel Hill, USA)

04.30pm-05.00pm *COFFEE BREAK*

*Chairpersons: C. Mussini* (Modena, Italy), *F. Maggiolo* (Bergamo, Italy)

05.00pm-05.30pm Cerebrospinal fluid biomarkers  
*M. Gisslen* (Goteborg, Sweden)

05.30pm-06.00pm Imaging the ageing HIV brain  
*J. Cole* (London, UK)

## POSTER SESSION

06.00pm-07.00pm *Chairpersons:*  
*A. Cingolani* (Rome, Italy), *G. Marchetti* (Milan, Italy)

08.00pm *DINNER*

# Day 2 - Friday, October 13<sup>th</sup>, 2017

## SESSION 2 - CNS HIV Treatment: 1. Effects of ART on early CNS infection

Chairpersons: **A. Di Biagio** (Genoa, Italy), **G. Guaraldi** (Modena, Italy)

- 09.00am-09.30am Current neurological problems and their trend over the last years  
**A. Antinori** (Rome, Italy)
- 09.30am-10.00am Impact of early treatment on viral persistence and inflammation  
**S. Spudich** (New Haven, USA)
- 10.00am-10.30am Impact of early treatment on neurocognitive function  
**K. Robertson** (Chapel Hill, USA)
- 10.30am-11.00am COFFEE BREAK

## SESSION 3 - CNS HIV Treatment: 2. Effects of ART on treated CNS infection

Chairpersons: **S. Bonora** (Turin, Italy), **A. De Luca** (Siena, Italy)

- 11.00am-11.30am PK and efficacy of new ARV drugs  
**A. Yilmaz** (Goteborg, Sweden)
- 11.30am-12.00pm Relevance of ART neuropenetration of importance - review of evidence pro/con  
**S. Letendre** (San Diego, USA)
- 12.00pm-12.30pm CNS drug toxicities  
**E. Martinez** (Barcelona, Spain)
- 12.30pm-01.00pm Neuropsychological performance, imaging and inflammation in ART-treated compared to HIV-negatives  
**A. Winston** (London, UK)



# Day 2 - Friday, October 13<sup>th</sup>, 2017

Chairpersons: **A. Gori** (Milan, Italy), **G. Rizzardini** (Milan, Italy)

02.00pm-02.30pm Asymptomatic CSF HIV escape  
**A. Calcagno** (Turin, Italy)

02.30pm-03.00pm Symptomatic and secondary CSF HIV escape  
**P. Cinque** (Milan, Italy)

03.00pm-03.30pm Brain imaging of CSF HIV escape  
**S. Gerevini** (Milan, Italy)

03.30pm-04.00pm Virological character of CSF HIV escape  
**S. Joseph** (Chapel Hill, USA)

04.00pm-04.30pm *COFFEE BREAK*

## ORAL PRESENTATIONS

04.30pm-06.00pm Chairpersons:  
**G. Nunnari** (Catania, Italy), **S. Rusconi** (Milan, Italy)

## POSTER SESSION

06.00pm-07.00pm Chairpersons:  
**S. Parisi** (Padua, Italy), **S. Lo Caputo** (Florence, Italy)

08.00pm *DINNER*

# Day 3 - Saturday, October 14<sup>th</sup>, 2017

## SESSION 4 - The CNS reservoir and its role in viral eradication

Chairpersons: **G. Di Perri** (Turin, Italy), **G. Ippolito** (Rome Italy)

- 09.00am-09.30am Effect of systemic and CNS inflammation on the CNS and ways to interact  
**P. Hunt** (San Francisco, USA)
- 09.30am-10.00am HIV tat, a pivotal molecule in CNS HIV latency, target for mitigation and biomarker of the CNS reservoir  
**A. Nath** (Bethesda, USA)
- 10.00am-10.30am Models of CNS cure/mitigation in primates  
**L. Gama** (Baltimore, USA)
- 10.30am-11.00am *COFFEE BREAK*
- Chairpersons: **A. d'Arminio Monforte** (Milan, Italy),  
**G. Poli** (Milan, Italy)
- 11.00am-11.30am Systemic HIV persistence, effects on morbidity and mortality and approaches to mitigation and cure  
**S. Deeks** (San Francisco, USA)
- 11.30am-12.00pm HIV Cure research relevant to the CNS  
**R.W. Price** (San Francisco, USA)
- 12.00pm-12.30pm FINAL REMARKS and CME Questionnaire compilation
- 12.30pm-01.00pm *LUNCH*

# General Informations

## CONGRESS VENUE

ALBERGO DELL'AGENZIA  
Via Fossano, 21, 12042 Pollenzo CN  
Tel: [+39] 0172/458600

## ORGANIZING SECRETARIAT



Nadirex International Srl  
Via Riviera, 39 - 27100 Pavia  
Tel. +39.0382.525714/35  
Fax +39.0382.525736  
info@nadirex.com  
www.nadirex.com

## CME

The request for CME credits has been forwarded to the Italian Ministry of Health for Italian participants. **Nr. 265-201260 - Nr. 16,5 CME credits**

The Congress is intended for 100 participants.

**Physician:** *Infectious Diseases - Microbiology and Virology - Neurology - Psychiatry.*

**Psychologist:** *Psychotherapy - Psychology.*

# General Informations

## REGISTRATION

*Early Registration before September, 18th*

Euro 366,00 (€ 300,00 + 22% VAT)

*Late Registration after September, 18th*

Euro 427,00 (€ 350,00 + 22% VAT)

Congress registration: [www.neurohiv.com](http://www.neurohiv.com)

## THE REGISTRATION FEE INCLUDES:

- Participation in the scientific work
- Congress kit
- Certificate of attendance
- CME certificate
- Abstract Book
- Coffee breaks and working breakfasts for the whole period
- Thursday October, 12<sup>th</sup> Dinner
- Friday October, 13<sup>th</sup> Dinner

## CERTIFICATE OF ATTENDANCE

The Certificate of Attendance will be hand at the end of the Meeting to all the participants registered at the desk of the Organizing Secretariat.

## SLIDES AND INTERNET POINTS

A computerized projection will be provided by technicians.

Please provide the file of your presentation in electronic format.

All the Congress Presentations will be published on the website prior written authorization by the Speakers.

## OFFICIAL LANGUAGE

Official language: English.

Simultaneous translation will not be provided.

# General Informations

## ORAL COMMUNICATIONS AND POSTERS

The scientific programme of the conference will include Oral Communications and Posters' Sessions and Discussions of Posters. The Abstracts and the type of presentations will be selected by the Scientific Committee.

Abstracts must contain original data, not already presented on other occasions.

Abstracts must be in English and will be published in the Abstract Book.

Abstracts must be submitted exclusively using the on-line form, following the instructions available at [www.neurohiv.com](http://www.neurohiv.com).

The Organizing Secretariat will inform the first author on the abstract form, via e-mail, of the acceptance of the work, the format (oral communication or poster) and the date and time of presentation.

Twelve minutes will be allocated for the presentation of each communication, after which there will be a three minutes of discussion.

Size of Posters: 70 cm wide x 100 cm high. The mounting material is available at the display area.

The presence of the Author is required during the poster presentation.

## HOW TO SUBMIT THE ABSTRACT

The system will automatically send the notification of successful submission.

If you do not receive the notification, please contact the Organizing Secretariat at [info@nadirex.com](mailto:info@nadirex.com).

The person that submit the Abstract, must indicate the Presenting Author:

- Submitters and Presenting Author are responsible for the accuracy of all data submitted including correct spelling of names and institutions
- The Submitters must indicate the preferred presentation form (Oral Communication or Poster).

The choice is not binding.

- The Presenting Author will receive all the official communications from the Organizing Secretariat
- The Presenting Author must be registered to the Congress.

Any change must be immediately communicated to the Organizing Secretariat at [info@nadirex.com](mailto:info@nadirex.com).

In case of acceptance, the Abstract will be published and the Abstract Book will be distributed at the Congress.

## DEADLINE FOR ABSTRACT SUBMISSION

September 10<sup>th</sup>, 2017 - On-line submission.

September 15<sup>th</sup>, 2017 - Notification of acceptance of abstracts.

# REGISTRATION FORM

## SEVENTH INTERNATIONAL MEETING HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM

NeuroHIV2017

**OCTOBER, 12-14 2017**

POLLENZO-BRA (CN), ITALY

Fill in using block letters and send  
**within October, 11th**

Registration on-line:

[www.neurohiv.com](http://www.neurohiv.com)

### ALL THE FOLLOWING DATA ARE REQUESTED

Name ..... Surname .....  
Profession ..... Discipline .....  
Hospital ..... Address .....  
Postal Code ..... Town/City ..... Province .....  
Tel. .... Mobile Tel. ....  
Fax ..... E-mail .....

### INVOICE INFORMATION (MANDATORY) - Invoice headed to:

Name/Last name or company name .....  
Address .....  
Postal Code ..... Town/City ..... Province .....  
VAT Number ..... Fiscal Code .....  
Birth date ..... Birth place .....

### REGISTRATION FEES

*Early Registration before September, 18th* Euro 366,00 (€ 300,00 + 22% VAT)

*Late Registration after September, 18th* Euro 427,00 (€ 350,00 + 22% VAT)

### METHOD OF PAYMENT

Bank transfer headed to Nadirex International S.r.l. - c/o: Banca Ubi Banca - Filiale Pavia Porta Cavour  
Cab 11305 - Swift Code: BLOPIT22634 - IBAN: IT48A031111305000000030112

Credit Card: Visa - Master Card - American Express

Card Number ..... CV2 code ..... Expiry date .....

Credit Card holder ..... Signature .....

*I authorise the use of my personal data in accordance with Legislative Decree 196/2003*

Date..... Signature .....

WITH THE SUPPORT OF



ViiV Healthcare S.r.l. è sponsor commerciale parziale del presente Evento

Il presente Evento non è soggetto a deposito AIFA ai sensi e per gli effetti di cui all'art. 124 del D. Lgs. 219/06

